Abstract
Early in the pandemic, concerns were raised about the potential for serious and widespread neurological and psychiatric adverse outcomes following COVID-19, on the basis of a systematic review of observational studies done in patients infected during previous coronavirus epidemics.1 Interpretation was hampered by the absence of a comparison group of individuals who had similar infections. The first large-scale attempt to redress this issue was published by Maxime Taquet and colleagues2 who found, using real-world data, that a first psychiatric diagnosis was more common in patients with COVID-19 in the 14–90 days after SARS-CoV-2 infection than in those with several other acute illnesses.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
